NIHR CRN's white paper

UK’s clinical research network achieves 65 first global patients in 3 years

Lydia Sebastian Event News Leave a Comment

NIHR CRN's white paper

Performance figures show that the UK is open for business

The National Institute for Health Research (NIHR) Clinical Research Network has reached a
milestone in study set-up achievements by recruiting 65 first global patients in commercial studies
in the last three years.

With many clinical research studies recruiting patients simultaneously from all over the world, a
“global first patient” is a key performance indicator for the life-sciences industry. It demonstrates
which countries can support the rapid set-up of studies.

Since the Network started to record first global patients, it has achieved 86 in total. Over the last
five years the Network has also seen an upturn in the number of studies coming into the country,
623 new commercial contract studies last year, no doubt helped by this achievement. This is a
signal that the UK is now a globally competitive market in which to conduct clinical research.

These achievements are primarily the result of the work undertaken to improve study set-up times.
The Network has reduced the time taken for studies to get underway by 82 per cent over the last
five years. The median number of calendar days taken to obtain permission from National Health
Service (NHS) sites was 20 days in 2014/15 compared to 115 days in 2010/11.

Commenting on the news, Dr Jonathan Sheffield, Chief Executive Officer of the NIHR Clinical
Research Network, said:

“Achieving a first global patient shows that the UK has the infrastructure to compete on the
international stage in terms of clinical research study set-up. The Network is driving down the time
it takes to set up a study in the UK and this in turn is being rewarded with a record number of these
achievements.”

Paul Duffy, Executive Director Clinical Research UK & ROI, MSD (known as Merck in the US and
Canada) said:

“Rapid study set up is integral to attracting new clinical trials and companies to the UK, and is a
key element of the UK Government’s strategy for UK Life Sciences. We have seen an 80 per cent
increase in the number of studies coming into the UK in the past two years. Our growing
relationship with NIHR has played a key role by helping to facilitate quicker set-up time for MSD
studies throughout the UK.”

Dr Matt Cooper, Business Development and Marketing Director of the NIHR Clinical Research
Network, said:

“The commercial research landscape here has changed dramatically over recent years and our
performance figures show that the UK is well and truly open for business. These changes are
helping to drive growth and investment but, more importantly, they also mean that patients using
our National Health Service are getting access to cutting edge treatments and technologies
sooner.”

More than 100,000 people have participated in commercial contract research supported by the
NIHR Clinical Research Network over the last five years. Last financial year the Network recruited
nearly 35,000 participants to studies sponsored by the life-sciences industry – a 35 per cent
increase on the previous year.

These improvements are also testament to the ongoing work of the wider NIHR (www.nihr.ac.uk) –
the research arm of the UK’s National Health Service (NHS). The NIHR celebrates its 10th
anniversary this year. It is funded by the UK Government and invests over £1 billion per year into
research programmes, projects and research infrastructure in England. The NIHR plays a key role
in the Government’s strategy for economic growth, attracting investment by the life-sciences
industries through its world-class infrastructure for health research which represents the most
integrated health research system in the world.

Dr Matt Cooper, Business Development and Marketing Director for the NIHR Clinical Research
Network, will be giving a 20 minute case study presentation on day one of the BioPharmAsia
Convention 2016 Clinical Trials Session (read Matt Cooper’s biography). Entitled “Looking west –
The UK as a clinical trial destination”, Dr Cooper’s session will describe how the UK’s clinical
research environment has evolved to make the achievements listed here possible.

Download the full white paper here

The NIHR Clinical Research Network team will be available to meet with delegates at exhibition
stand B22 throughout the event. If you would like to arrange a one to one meeting please use the
contacts below:

Dr Teresa Fortune, Head of Business Development and Marketing, t. +44 (0)7881337362 |
e. teresa.fortune@nihr.ac.uk

Alternatively you can see a full list of studies that have achieved first global patient and find out
more about our Study Support Service by visiting www.crn.nihr.ac.uk/biopharmaasia

About NIHR
The National Institute for Health Research (NIHR) Clinical Research Network has recruited 65 first global patients in commercial studies in the last three years. These achievements are primarily the result of improving study set-up times by 82 per cent over the last five years. The Network has also seen an upturn in the number of studies coming into the country over the same period. This is a signal that the UK is now a globally competitive market in which to conduct clinical research.

Leave a Reply

Your email address will not be published. Required fields are marked *